{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:13:40Z","timestamp":1793812420446,"version":"4.6.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jns.2025.123628","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:23:41Z","timestamp":1752679421000},"page":"123628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["First analysis of the Myasthenia Gravis SPOTLIGHT Registry: outcomes with eculizumab and ravulizumab"],"prefix":"10.1016","volume":"476","author":[{"suffix":"Jr","given":"James F.","family":"Howard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dubravka","family":"Dodig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Zeinali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir P.","family":"Macwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Yegin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Pulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ema","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpa","family":"Narayanaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jns.2025.123628_bb0005","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: Past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.jns.2025.123628_bb0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: Classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol. Clin."},{"issue":"5-6","key":"10.1016\/j.jns.2025.123628_bb0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jns.2025.123628_bb0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","article-title":"Incidence, epidemiology, and transformation of ocular myasthenia gravis: A population-based study","volume":"205","author":"Hendricks","year":"2019","journal-title":"Am. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.jns.2025.123628_bb0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3988\/jcn.2009.5.2.53","article-title":"Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status","volume":"5","author":"Oh","year":"2009","journal-title":"J. Clin. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2025.123628_bb0030","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.jns.2025.123628_bb0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: The role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2025.123628_bb0040","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1196\/annals.1405.034","article-title":"Treatment of myasthenia gravis by preventing acetylcholine receptor modulation","volume":"1132","author":"Losen","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"7","key":"10.1016\/j.jns.2025.123628_bb0045","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"T\u00fcz\u00fcn","year":"2003","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jns.2025.123628_bb0050","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s13311-015-0398-y","article-title":"Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis","volume":"13","author":"Guptill","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jns.2025.123628_bb0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/NDT.S8915","article-title":"Current and emerging therapies for the treatment of myasthenia gravis","volume":"7","author":"Mantegazza","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"4","key":"10.1016\/j.jns.2025.123628_bb0060","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2025.123628_bb0065","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"MG Study Group, A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2025.123628_bb0070","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: Clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2025.123628_bb0075","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2025.123628_bb0080","series-title":"Soliris (eculizumab) [prescribing information]","year":"2025"},{"key":"10.1016\/j.jns.2025.123628_bb0085","series-title":"Soliris (eculizumab) [European public assessment report], Levallois-Perret, France: Alexion Europe SAS","year":"2025"},{"key":"10.1016\/j.jns.2025.123628_bb0090","author":"Pharmaceuticals and Medical Devices Agency"},{"key":"10.1016\/j.jns.2025.123628_bb0095","series-title":"Ultomiris (ravulizumab) [prescribing information]","year":"2024"},{"issue":"5","key":"10.1016\/j.jns.2025.123628_bb0100","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM. Evid."},{"issue":"12","key":"10.1016\/j.jns.2025.123628_bb0105","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2025.123628_bb0110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"REGAIN Study Group, Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2025.123628_bb0115","author":"National Institutes of Health"},{"issue":"7","key":"10.1016\/j.jns.2025.123628_bb0120","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2025.123628_bb0125","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG COMPOSITE and MG-QOL15 Study Group, MG-ADL: Still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.jns.2025.123628_bb0130","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","article-title":"'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume":"267","author":"Vissing","year":"2020","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2025.123628_bb0135","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: Recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann. Thorac. Surg."},{"issue":"1","key":"10.1016\/j.jns.2025.123628_bb0140","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/mus.28417","article-title":"Standardization of myasthenia gravis outcome measures in clinical practice: A report of the MGFA Task Force","volume":"72","author":"Ruzhansky","year":"2025","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2025.123628_bb0145","author":"Myasthenia Gravis Quality of Life-15 Revised (MG-QOL15r)"},{"issue":"6","key":"10.1016\/j.jns.2025.123628_bb0150","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2025.123628_bb0155","series-title":"AANEM Annual Meeting, Phoenix, AZ","article-title":"Eculizumab and ravulizumab: A case series","author":"Gordon","year":"2023"},{"key":"10.1016\/j.jns.2025.123628_bb0160","series-title":"AANEM Annual Meeting, Phoenix, AZ","article-title":"A case series of patients with generalized myasthenia gravis treated with the complement component C5 inhibitors eculizumab and ravulizumab","author":"Scheiner","year":"2023"},{"issue":"8","key":"10.1016\/j.jns.2025.123628_bb0165","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","article-title":"REGAIN Study Group, Eculizumab improves fatigue in refractory generalized myasthenia gravis","volume":"28","author":"Andersen","year":"2019","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.jns.2025.123628_bb0170","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420904207","article-title":"Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis","volume":"13","author":"Oyama","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"8","key":"10.1016\/j.jns.2025.123628_bb0175","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: Results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2025.123628_bb0180","series-title":"AAN Annual Meeting, Denver, CO","article-title":"Long-term efficacy and safety of ravulizumab, a long-acting terminal complement inhibitor in adults with AChR Ab+ generalized myasthenia gravis: Final results from the phase 3 CHAMPION MG open-label extension","author":"Vu","year":"2024"},{"key":"10.1016\/j.jns.2025.123628_bb0185","series-title":"AAN Annual Meeting, Denver, CO, Apr","first-page":"13","article-title":"Patterns of steroid use and outcomes in US patients with generalized myasthenia gravis (gMG) receiving C5 inhibitor therapy (C5IT)","author":"Yee","year":"2024"},{"issue":"3","key":"10.1016\/j.jns.2025.123628_bb0190","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2025.123628_bb0195","series-title":"AANEM Annual Meeting, Phoenix, AZ","article-title":"Change in concomitant therapies for generalized myasthenia gravis in patients receiving eculizumab: A retrospective analysis of registry data","author":"Pulley","year":"2023"},{"key":"10.1016\/j.jns.2025.123628_bb0200","series-title":"Myasthenia Gravis Foundation of America (MGFA) at the AANEM Annual Meeting, Savannah, GA","article-title":"Change in concomitant immunosuppressive therapies for generalized myasthenia gravis in patients receiving complement C5 inhibitor therapies: A retrospective analysis of registry data","author":"Nowak","year":"2024"},{"issue":"2","key":"10.1016\/j.jns.2025.123628_bb0205","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/mus.25529","article-title":"QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis","volume":"56","author":"Howard","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2025.123628_bb0210","series-title":"AAN Annual Meeting, Denver, CO","article-title":"Effectiveness and safety of transitioning to ravulizumab from eculizumab in patients with generalized myasthenia gravis: Evidence from a global registry","author":"Sabatella","year":"2024"},{"key":"10.1016\/j.jns.2025.123628_bb0215","series-title":"Congress of the European Academy of Neurology, Helsinki, Finland","article-title":"Safety and effectiveness of ravulizumab in generalized myasthenia gravis: Evidence from a global registry","author":"Narayanaswami","year":"2024"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2500245X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2500245X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:51:57Z","timestamp":1762210317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2500245X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"alternative-id":["S0022510X2500245X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.123628","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First analysis of the Myasthenia Gravis SPOTLIGHT Registry: outcomes with eculizumab and ravulizumab","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.123628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123628"}}